ClinicalTrials.gg
CompletedNCT02100228EMANATEUpdated May 23, 2018Results posted

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

A Phase 4 interventional study of Apixaban and Parenteral heparin and/or oral Vitamin K antagonist in Atrial Fibrillation, sponsored by Pfizer. Completed at 165 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-23.

Sponsored by Pfizer · Phase 4, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing apixaban in Atrial Fibrillation — 11 open to participants now, 12 under way, 4 of them phase 3. apixaban · Atrial Fibrillation.

Enrollment
8th of 31
1,500 · median 586
Started
2014
with 4 others
Phase 4
14 of 31
6 open now
Registered
6th of 31
by date
Lead sponsor
2 of 31
Pfizer

Among the 31 studies testing apixaban in Atrial Fibrillation, this one is the 8th largest by enrollment, is one of 5 that started in 2014, is one of 14 in phase 4, and was the 6th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

11 of the 31 studies testing apixaban in Atrial Fibrillation are open now, in 10 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing apixaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

Some people can develop an abnormal heart beat known as "Atrial fibrillation" or "AF" that puts them at risk of developing clots in the heart. Those clots can travel in the blood circulation to the brain and cause a brain attack ("a stroke"). To prevent those clots forming, blood thinners (anti-coagulants) are used. Apixaban is a blood thinner that works by stopping one of the blood substances required for clotting ("Factor Xa"). It is approved and used to prevent clots forming in people with "AF". Other established blood thinners work by stopping clotting substances being made, known as "Vitamin K antagonists" or "VKAs". An example of this type is Warfarin (Coumadin). The good effects of all blood thinners are preventing clots, and they may also have bad effects of increasing the chance of bleeding. People with "AF", abnormal heart beat, may benefit from changing it back to a normal regular rhythm, known medically as "cardioversion". When this is done, people are currently most commonly treated with a "VKA" blood thinner (e.g. warfarin). The purpose of this study is to assess the good and bad effects ("efficacy" and "safety") of apixaban compared with warfarin in people with "AF" in whom an early cardioversion is planned.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • apixaban
  • oral anticoagulant
  • non-valvular atrial fibrillation
  • cardioversion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with non-valvular atrial fibrillation (as documented by (ECG) at Visit 1) indicated for cardioversion and initiation of anticoagulation in accordance with the approved local label. Subjects presenting with atrial flutter with no evidence of atrial fibrillation are not eligible for enrolment.
  • Age ≥18 years (Age ≥ 19 years for Korea only and Age ≥ 20 years for Japan only).
  • Evidence of a personally signed and dated document indicating that the subject (or their legally-recognized representative) has been informed of all pertinent aspects of the study.
  • The subject is willing to provide contact details for at least one alternate person for study staff to contact regarding their whereabouts, should the subject be lost-to-follow-up over the course of the study. (Subject to IRB/IEC approval)
  • Female subjects of must agree to use a highly effective method of throughout the study and for at least 28 days after the last dose of assigned treatment. A subject is of childbearing potential if, in the opinion of the investigator, she is biologically capable of having children and is sexually active.
  • Subjects who are willing and able to comply with scheduled visits, treatment plan, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Subjects having taken more than 48 hours of an anticoagulant (oral and/or parenteral) immediately prior to randomization.
  • to apixaban or usual care (eg, VKA) in accordance with the approved local label.
  • Severe haemodynamically compromised subjects requiring emergent cardioversion.
  • Patients with hemodynamically significant mitral stenosis, mechanical or biological prosthetic valve or valve repair.
  • Conditions other than atrial fibrillation that require chronic anticoagulation (eg, a prosthetic heart valve).
  • Simultaneous treatment with both aspirin and a thienopyridine (eg, clopidogrel, ticlopidine, prasugrel) or simultaneous treatment with both aspirin and ticagrelor.
  • Pregnant females; breastfeeding females; females of who are unwilling or unable to use a highly effective method of as outlined in this protocol for the duration of the study and for at least 28 days after last dose of product.
  • Participation in other studies involving investigational drug(s) (Phases 1-4) within 30 days before the current study begins and/or during study participation. Note: Subjects cannot be randomized into this study more than once.
  • Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  • Subjects who are investigational site staff members directly involved in the conduct of the trial and their family members, site staff members otherwise supervised by the Investigator, or subjects who are BMS/Pfizer employees directly involved in the conduct of the trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,500 participants (actual)

Study arms

  • Experimental
    Apixaban

    Drug: Apixaban

  • Active comparator
    Parenteral heparin and/or oral Vitamin K antagonist

    Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)

    Drug: Parenteral heparin and/or oral Vitamin K antagonist

Interventions

  • Oral, 2.5 or 5 mg BID

  • DrugParenteral heparin and/or oral Vitamin K antagonist

    Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Acute Stroke Event

    An acute stroke was defined as a new, important neurological insufficiency of rapid onset that lasted for at least 24 hours and that was not due to a readily identifiable non-vascular cause (like brain tumor or trauma).

    Time frame: Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)

  2. Number of Participants With Systemic Embolism Event

    Systemic embolism occurred in participant when there was a clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which was supported by evidence of embolism from surgical specimens, autopsy, angiography, or other objective testing.

    Time frame: Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)

  3. Number of Participants With Major Bleeding Event

    Major bleeding was defined as clinically evident bleeding that was accompanied by one or more of the following: a decrease in hemoglobin of 2 gram per deciliter or more, a transfusion of 2 or more units of packed red blood cells, bleeding that was fatal or bleeding that occurred in at least one of the following critical sites: intracranial, intra-spinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed was not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal.

    Time frame: Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)

  4. Number of Participants With Clinically Relevant Non-Major Bleeding Events

    Clinically relevant non-major bleeding was defined as the clinically evident bleeding that consisted of any bleeding that compromised hemodynamics, that led to hospitalization, subcutaneous hematoma larger than 25/100 centimeter square if there was a traumatic cause, intramuscular hematoma documented by ultrasonography, epistaxis, gingival bleeding occurred spontaneously, hematuria that was macroscopic and was spontaneous, macroscopic gastrointestinal hemorrhage included at least one episode of melena or hematemesis, rectal blood loss, hemoptysis or any other bleeding type considered to have clinical consequences for a participant, such as medical intervention, the need for unscheduled contact with a physician, or temporary cessation of a study drug, or associated with pain or impairment of activities of daily life.

    Time frame: Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)

  5. Number of Participants With All Cause Death

    Time frame: Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)

Secondary outcomes

  1. Time to First Attempt of Cardioversion

    Cardioversion was an effective method of converting an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia to normal rhythm using electricity or drugs. First attempt of cardioversion was defined as the first time the participant was admitted for the cardioversion procedure.

    Time frame: Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)

  2. Number of Participants With Different Type of Cardioversion Events

    Cardioversion was an effective method of converting an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia to normal rhythm using different type of cardioversion events i.e. electrical and pharmacologic. Electrical cardioversion was a procedure in which an electric current was used to reset the heart's rhythm back to its regular pattern (normal sinus rhythm). Pharmacologic cardioversion, also called chemical cardioversion, used antiarrhythmia medication instead of an electrical shock.

    Time frame: Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)

  3. Number of Cardioversion Attempt of Participants

    Cardioversion attempts were defined as the number of times the participant was admitted to hospital for the cardioversion procedure and not the number of attempts during a single hospital admission.

    Time frame: Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)

  4. Number of Participants With Their Rhythm Status

    Rhythm status was further distinguished into sinus rhythm, atrial fibrillation and atrial flutter. Sinus rhythm was defined as a normal heartbeat. Atrial fibrillation was an irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications and atrial flutter was a common abnormal heart rhythm that was usually associated with a fast heart rate (100 or more heart beats per minute).

    Time frame: Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)

  5. Duration of Hospital Stay of Participants

    Duration of hospital stay was defined as the number of hours from hospital admission to hospital discharge followed by early cardioversion.

    Time frame: Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)

  6. Number of Participants Who Used Image Guidance Approach

    An image-guided approach helped cardioversion earlier than the conventional minimum of 3 weeks of anticoagulation that would normally be required prior to cardioversion. Transesophageal echocardiography (TEE or TOE) and computed tomography (CT) were 2 image-guided approaches that were used in this study.

    Time frame: Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)

07

Results

Posted Apr 10, 2018
Limitations and caveats
The prioritization of outcome measures is not mentioned in the study documents (Statistical Analysis Plan and Protocol). The prioritization of outcome measures is based on team's discretion.

Participant flow

Participant flow — Overall Study
MilestoneApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)
Started753747
Completed678657
Not completed7590
Withdrew: Other1919
Withdrew: Administrative reason01
Withdrew: Inclusion/exclusion criteria not met1216
Withdrew: Non-compliance03
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject2737
Withdrew: Adverse event1612
Withdrew: Death11

Outcome measures

PrimaryNumber of Participants With Acute Stroke Event

An acute stroke was defined as a new, important neurological insufficiency of rapid onset that lasted for at least 24 hours and that was not due to a readily identifiable non-vascular cause (like brain tumor or trauma).

Time frame:
Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)
Reported as:
Number · participants
Number of Participants With Acute Stroke Event
participantsApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)
Number of Participants With Acute Stroke Event06
Statistical analysis
  • Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) · Fisher Exact · p = 0.0151 (nominal p-value) · Risk ratio (rr): 0.0000 · 95% CI 0.0000 to 0.6425
PrimaryNumber of Participants With Systemic Embolism Event

Systemic embolism occurred in participant when there was a clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which was supported by evidence of embolism from surgical specimens, autopsy, angiography, or other objective testing.

Time frame:
Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)
Reported as:
Number · participants
Number of Participants With Systemic Embolism Event
participantsApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)
Number of Participants With Systemic Embolism Event0 (0 to 0)0 (0 to 0)
PrimaryNumber of Participants With Major Bleeding Event

Major bleeding was defined as clinically evident bleeding that was accompanied by one or more of the following: a decrease in hemoglobin of 2 gram per deciliter or more, a transfusion of 2 or more units of packed red blood cells, bleeding that was fatal or bleeding that occurred in at least one of the following critical sites: intracranial, intra-spinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed was not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal.

Time frame:
Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)
Reported as:
Number · participants
Number of Participants With Major Bleeding Event
participantsApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)
Number of Participants With Major Bleeding Event36
Statistical analysis
  • Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) · Fisher Exact · p = 0.3378 (nominal p-value) · Risk ratio (rr): 0.4905 · 95% CI 0.1046 to 2.0678
PrimaryNumber of Participants With Clinically Relevant Non-Major Bleeding Events

Clinically relevant non-major bleeding was defined as the clinically evident bleeding that consisted of any bleeding that compromised hemodynamics, that led to hospitalization, subcutaneous hematoma larger than 25/100 centimeter square if there was a traumatic cause, intramuscular hematoma documented by ultrasonography, epistaxis, gingival bleeding occurred spontaneously, hematuria that was macroscopic and was spontaneous, macroscopic gastrointestinal hemorrhage included at least one episode of melena or hematemesis, rectal blood loss, hemoptysis or any other bleeding type considered to have clinical consequences for a participant, such as medical intervention, the need for unscheduled contact with a physician, or temporary cessation of a study drug, or associated with pain or impairment of activities of daily life.

Time frame:
Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)
Reported as:
Number · participants
Number of Participants With Clinically Relevant Non-Major Bleeding Events
participantsApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)
Number of Participants With Clinically Relevant Non-Major Bleeding Events1113
Statistical analysis
  • Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) · Fisher Exact · p = 0.6851 (nominal p-value) · Risk ratio (rr): 0.8300 · 95% CI 0.3433 to 1.8916
PrimaryNumber of Participants With All Cause Death
Time frame:
Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)
Reported as:
Number · participants
Number of Participants With All Cause Death
participantsApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)
Number of Participants With All Cause Death21
Statistical analysis
  • Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) · Fisher Exact · p = >0.9999 (nominal p-value) · Risk ratio (rr): 1.9841 · 95% CI 0.1866 to 53.9968
SecondaryTime to First Attempt of Cardioversion

Cardioversion was an effective method of converting an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia to normal rhythm using electricity or drugs. First attempt of cardioversion was defined as the first time the participant was admitted for the cardioversion procedure.

Time frame:
Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)
Reported as:
Median · days
Time to First Attempt of Cardioversion
daysApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)
Time to First Attempt of Cardioversion2.0 (1 to 93)2.0 (1 to 126)
SecondaryNumber of Participants With Different Type of Cardioversion Events

Cardioversion was an effective method of converting an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia to normal rhythm using different type of cardioversion events i.e. electrical and pharmacologic. Electrical cardioversion was a procedure in which an electric current was used to reset the heart's rhythm back to its regular pattern (normal sinus rhythm). Pharmacologic cardioversion, also called chemical cardioversion, used antiarrhythmia medication instead of an electrical shock.

Time frame:
Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)
Reported as:
Number · participants
Number of Participants With Different Type of Cardioversion Events
participantsApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)
Electrical461464
Pharmacologic3530
SecondaryNumber of Cardioversion Attempt of Participants

Cardioversion attempts were defined as the number of times the participant was admitted to hospital for the cardioversion procedure and not the number of attempts during a single hospital admission.

Time frame:
Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)
Reported as:
Number · participants
Number of Cardioversion Attempt of Participants
participantsApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)
No Cardioversion Attempt234224
1 Cardioversion Attempt488496
More than 2 Cardioversion Attempts3127
SecondaryNumber of Participants With Their Rhythm Status

Rhythm status was further distinguished into sinus rhythm, atrial fibrillation and atrial flutter. Sinus rhythm was defined as a normal heartbeat. Atrial fibrillation was an irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications and atrial flutter was a common abnormal heart rhythm that was usually associated with a fast heart rate (100 or more heart beats per minute).

Time frame:
Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)
Reported as:
Number · participants
Number of Participants With Their Rhythm Status
participantsApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)
Normal Sinus12
Atrial Fibrillation715704
Atrial Flutter36
SecondaryDuration of Hospital Stay of Participants

Duration of hospital stay was defined as the number of hours from hospital admission to hospital discharge followed by early cardioversion.

Time frame:
Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)
Reported as:
Median · hours
Duration of Hospital Stay of Participants
hoursApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)
Duration of Hospital Stay of Participants45.36 (0.4 to 747.0)49.47 (0.6 to 709.6)
SecondaryNumber of Participants Who Used Image Guidance Approach

An image-guided approach helped cardioversion earlier than the conventional minimum of 3 weeks of anticoagulation that would normally be required prior to cardioversion. Transesophageal echocardiography (TEE or TOE) and computed tomography (CT) were 2 image-guided approaches that were used in this study.

Time frame:
Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)
Reported as:
Number · participants
Number of Participants Who Used Image Guidance Approach
participantsApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)
Number of Participants Who Used Image Guidance Approach383399

Adverse events

Collected over From baseline up to 30 days after cardioversion or 90 days after randomization, if cardioversion was not performed. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apixaban1/735 (0.1%)100/735 (13.6%)70/735 (9.5%)
Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care)3/721 (0.4%)112/721 (15.5%)101/721 (14%)
Most frequent serious events
Showing 10 of 142
Most frequent serious events
EventApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)
ATRIAL FIBRILLATIONCardiac disorders27/73540/721
CARDIAC FAILURE CONGESTIVECardiac disorders9/7357/721
CARDIAC FAILURECardiac disorders5/7357/721
ATRIAL FLUTTERCardiac disorders3/7356/721
CORONARY ARTERY DISEASECardiac disorders2/7356/721
PNEUMONIAInfections and infestations3/7355/721
ACUTE KIDNEY INJURYRenal and urinary disorders1/7355/721
ATRIAL THROMBOSISCardiac disorders0/7353/721
MITRAL VALVE PROLAPSECardiac disorders0/7353/721
OVERDOSEInjury, poisoning and procedural complications0/7353/721
Most frequent other events
Most frequent other events
EventApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)
ATRIAL FIBRILLATIONCardiac disorders43/73546/721
INTERNATIONAL NORMALISED RATIO INCREASEDInvestigations0/73527/721
INTERNATIONAL NORMALISED RATIO ABNORMALInvestigations0/73519/721
ATRIAL THROMBOSISCardiac disorders17/73513/721
DYSPNOEARespiratory, thoracic and mediastinal disorders15/7358/721

Baseline characteristics

Full analysis set included all randomized participants.

Age, Continuous
Age, Continuous(years)ApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)Total
Mean64.7 ± 12.1964.5 ± 12.7664.6 ± 12.47
Sex: Female, Male
Sex: Female, Male(Participants)ApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)Total
Female248250498
Male5054971002
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)Total
Hispanic or Latino8917
Not Hispanic or Latino10099199
Unknown or Not Reported6456391284
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ApixabanParenteral Heparin/Oral Vitamin K Antagonist (Usual Care)Total
White6546481302
Black or African American212041
Asian7876154
Other033
08

Study locations

165 sites
  • Brookwood Medical Center
    Birmingham, Alabama 35209, United States
  • Cardiovascular Associates of the Southeast, LLC
    Birmingham, Alabama 35243, United States
  • Integrated Medical Services, Inc./IMS Cardiology
    Avondale, Arizona 85392, United States
  • Chula Vista Cardiac Center
    Chula Vista, California 91910, United States
  • Hartford Hospital
    Hartford, Connecticut 06102, United States
  • Certified Physician Investigator Research Group LLC
    Altamonte Springs, Florida 32714, United States
  • Orlando Heart Specialists
    Altamonte Springs, Florida 32714, United States
  • The University of Chicago Medical Center Investigational Drug Service Pharmacy (office/storage)
    Chicago, Illinois 60637, United States
  • The University of Chicago Medical Center Investigational Drug Service Pharmacy
    Chicago, Illinois 60637, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Chicago Medical Research, LLC
    Hazel Crest, Illinois 60429, United States
  • Franciscan Physician Network-Indiana Heart Physicians
    Indianapolis, Indiana 46237, United States
  • Franciscan St. Francis Health
    Indianapolis, Indiana 46237, United States
  • UK Good Samaritan Medical Office Building
    Lexington, Kentucky 40508-2678, United States
  • Good Samaritan Hospital
    Lexington, Kentucky 40508-3008, United States
  • University of Kentucky Medical Center Gill Heart Institute
    Lexington, Kentucky 40536-0200, United States
  • University of Kentucky Gill Heart Institute
    Lexington, Kentucky 40536, United States
  • University of Kentucky HealthCare/Albert. B, Chandler Hospital
    Lexington, Kentucky 40536, United States
  • Aim Clinic
    Louisville, Kentucky 40202, United States
  • Cardiology Outpatient Clinic
    Louisville, Kentucky 40202, United States
  • University of Louisville Clinical Trials Unit
    Louisville, Kentucky 40202, United States
  • University of Louisville Hospital
    Louisville, Kentucky 40202, United States
  • Robley Rex VA Medical Center
    Louisville, Kentucky 40206, United States
  • Alexandria Cardiology Clinic
    Alexandria, Louisiana 71301, United States
  • University of Massachusetts Worcester Research Pharmacy
    Worcester, Massachusetts 01655, United States
  • University of Massachusetts Worcester
    Worcester, Massachusetts 01655, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • Abbott Northwestern Hopsital - Allina Health System
    Minneapolis, Minnesota 55407, United States
  • Minneapolis Heart Institute Foundation
    Minneapolis, Minnesota 55407, United States
  • University of Missouri Health Care System
    Columbia, Missouri 65212, United States
  • University of Missouri Health System, Investigational Drug Serivce
    Columbia, Missouri 65212, United States
  • University of Missouri Health System
    Columbia, Missouri 65212, United States
  • Saint Luke's Lipid and Diabetes Research Center
    Kansas City, Missouri 64111, United States
  • Mercy Hospital St. Louis
    Saint Louis, Missouri 63141, United States
  • Electrophysiology Associates
    Hackensack, New Jersey 07601, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Robert Wood Johnson University Hospital
    New Brunswick, New Jersey 08901, United States
  • Rutgers Robert Wood Johnson Medical School Cardiovascular Institute
    New Brunswick, New Jersey 08901, United States
  • State University of New York (SUNY) Downstate Medical Center
    Brooklyn, New York 11203, United States
  • New York-Presbyterian/Queens
    Flushing, New York 11355, United States
  • Columbia University Medical Center/NY Presbyterian Hospital
    New York, New York 10032, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • ProMedica Physicians Cardiology
    Oregon, Ohio 43616, United States
  • ProMedica Toledo Hospital
    Toledo, Ohio 43606, United States
  • ProMedica Physicians Cardiology
    Toledo, Ohio 43615, United States
  • Hillcrest Medical Center Pharmacy
    Tulsa, Oklahoma 74104, United States
  • Oklahoma Heart Institute at Hillcrest Medical Center
    Tulsa, Oklahoma 74104, United States
  • Oklahoma Heart Institute
    Tulsa, Oklahoma 74104, United States
  • Cardiology Consultants of Philadelphia
    Bristol, Pennsylvania 19007, United States
  • Bryn Mawr Hospital
    Bryn Mawr, Pennsylvania 19010, United States
  • Bryn Mawr Medical Specialist Association
    Bryn Mawr, Pennsylvania 19010, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Pennsylvania Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Einstein Healthcare Network
    Philadelphia, Pennsylvania 19141, United States
  • Cardiology consultants of Philadelphia
    Yardley, Pennsylvania 19067, United States
  • Baptist Hospital of Southeast Texas - Beaumont
    Beaumont, Texas 77701, United States
  • Southeast Texas Cardiology Associates II, L.L.P.
    Beaumont, Texas 77702, United States
  • Southeast Texas Cardiology Associates II, L.L.P
    Beaumont, Texas 77702, United States
  • Southeast Texas Clinical Research Center
    Beaumont, Texas 77702, United States
  • Utah Cardiology, PC
    Layton, Utah 84041, United States
  • Cardiovascular Associates of Virginia-Bon Secours St. Mary's Hospital
    Midlothian, Virginia 23114, United States
  • St. Francis Medical Center
    Midlothian, Virginia 23114, United States
  • Dominion Cardiovascular Specialists PLLC
    Richmond, Virginia 23225, United States
  • Sint-Franciskusziekenhuis
    Heusden-Zolder, Limburg 3550, Belgium
  • University Hospital Ghent
    Gent, Oost-vlaanderen 9000, Belgium
  • UZ Leuven
    Leuven, Vlaams Brabant 3000, Belgium
  • Algemeen Ziekenhuis Klina
    Brasschaat, 2930, Belgium
  • Grand Hopital de Charleroi asbl
    Gilly, 6060, Belgium
  • Jessa Ziekenhuis-Campus Virga Jesse
    Hasselt, 3500, Belgium
  • AZ Delta
    Roeselare, 8800, Belgium
  • Cliniques Universitatires UCL Mont-Godinne
    Yvoir, 5530, Belgium
  • Southlake Regional Health Centre
    Newmarket, Ontario L3Y 2P9, Canada
  • Institut de Cardiologie de Montreal -ICM / Montreal Heart Institute-MHI
    Montreal, Quebec H1T 1C8, Canada
  • McGill University Health Center
    Montreal, Quebec H3G 1A4, Canada
  • Regionshospitalet Silkeborg
    Silkeborg, Midtjylland DK-8600, Denmark
  • Slagelse Hospital
    Slagelse, Sjaelland DK-4200, Denmark
  • Sydvestjysk Sygehus Esbjerg
    Esbjerg, 6700, Denmark
  • Regionhospitalet Viborg
    Viborg, DK-8800, Denmark
  • Cardio Centrum Ludwigsburg Bietigheim
    Ludwigsburg, Baden-württemberg 71634, Germany
  • Charitè Campus Mitte/ Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie
    Berlin, 10117, Germany
  • Vivantes -Netzwerk fuer Gesundheit GmbH - Klinikum Neukoelln
    Berlin, 12351, Germany
  • Charité - Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • Vivantes Netzwerk fuer Gesundhelt GmbH, Humboldt Klinikum
    Berlin, 13509, Germany
  • Klinikum Links der Weser gGmbH
    Bremen, 28277, Germany
  • Medizinisches Versorgungszentrum am Küchwald GmbH
    Chemnitz, 09113, Germany
  • Klinikum Coburg gGmbH
    Coburg, 96450, Germany
  • Zentrum fuer klinische Pruefungen in der Facharztzentrum Dresden-Neustadt GbR
    Dresden, 01099, Germany
  • Praxisklinik Herz und Gefäße
    Dresden, 01324, Germany
  • Johanniter-Krankenhaus Rheinhausen GmbH/ Klinik fuer Kardiologie
    Duisburg, 47228, Germany
  • Krankenhaus Nordwest GmbH
    Frankfurt am Main, 60488, Germany
  • Johann-Wolfgang Goethe-Universitaet
    Frankfurt/Main, 60590, Germany
  • Universitatsmedizin Greifswald
    Greifswald, 17475, Germany
  • Universitätsklinikum Hamburg Eppendorf, Universitäres Herzzentrum Hamburg GmbH
    Hamburg, 20246, Germany
  • Unklinik Heidelberg
    Heidelberg, 69120, Germany
  • Klinikum Heidenheim
    Heidenheim, 89522, Germany
  • Klinikum Ingolstadt/ Medizinische Klinik I und IV
    Ingolstadt, 85049, Germany
  • Cardiocenter Rhythmologie
    Leipzig, 04289, Germany
  • Herzzentrum Leipzig GmbH/ Abteilung für Rhythmologie
    Leipzig, 04289, Germany
  • Katholisches Klinikum Mainz
    Mainz, 55131, Germany
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
    Mainz, 55131, Germany

Showing the first 100 of 165 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ezekowitz MD, Pollack CV Jr, Halperin JL, England RD, VanPelt Nguyen S, Spahr J, Sudworth M, Cater NB, Breazna A, Oldgren J, Kirchhof P. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018 Aug 21;39(32):2959-2971. doi: 10.1093/eurheartj/ehy148. PubMed 29659797 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Feb 2017, 30 months.

Results were first posted in Apr 2018, 1 year 2 months after primary completion.

Of 141 phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 81. This study's 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2014
First posted
Mar 31, 2014
StartActual
Jul 14, 2014
Primary completionActual
Feb 8, 2017
CompletionActual
Feb 8, 2017
Results first posted
Apr 10, 2018
Last update
May 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02100228
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 31, 2014
Start date
Jul 14, 2014
Primary completion
Feb 8, 2017
Completion
Feb 8, 2017
Results posted
Apr 10, 2018
Last update
May 23, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion